Home | Meeting coverage | ESMO 2022

Breast cancer early: 100 seconds ENG

ESMO 2022

Giuseppe Curigliano, MD

My highlights of ESMO22

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

Hope Rugo, MD

Roadmap for the adjuvant setting

DATA

ESMO 2022

Karen Gelmon, MD

Immuntherapy only for low risk patients?

BELLINI

ESMO 2022

Wolfgang Janni, MD

Dose dense is better

GIM

ESMO 2022

Diana Lüftner, MD

QoL and longterm toxicity

KEYNOTE-522

ESMO 2022

Michael Untch, MD

Consolidating data from prospective studies

GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT

ESMO 2022

Elzbieta Senkus, MD

Simple and cheap surgical technique may impact survival...

ESMO 2022

Nadia Harbeck, MD

Endocrine response in eBC

ADAPT & ADAPTcycle

ESMO 2022

Volkmar Müller, MD

Reduction of peripheral neuropathy with taxane therapy

POLAR

ESMO 2022

Nadia Harbeck, MD

Long-term data on dose density therapy in chemotherapy

GIM

ESMO 2022

Véronique Diéras, MD

Dose-dense therapy is beneficial for all patients

GIM

ESMO 2022

Alessandra Gennari, MD

DD is the champion!

GIM

ESMO 2022

Elzbieta Senkus, MD

Hand cooling and compression both effective in...

Polar

ESMO 2022

Karen Gelmon, MD

Dose-dense standard of care is the optimal care

GIM

Breast cancer early: 100 seconds Multi Language

ESMO 2022

Véronique Diéras, MD

Schéma dose-dense bénéfique pour toutes les patientes

GIM

ESMO 2022

Elzbieta Senkus, MD

Chłodzenie rąk i terapia kompresyjna skutecznie...

Polar

ESMO 2022

Giuseppe Curigliano, MD

I miei punti salienti di ESMO22

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

Alessandra Gennari, MD

Il vincitore e’ il dose dense!!

GIM

ESMO 2022

Michael Untch, MD

Datele trialurilor se consolideata

GIM, MONARCH-3, TEAMS, monarchHER, KEYNOTE-522, ADAPT

ESMO 2022

Elzbieta Senkus, MD

Rosta i tania technika chirurgiczna może wpływać na...

Breast cancer early: Discussions

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

How to deal with the negative SERD data?

AMEERA, aceLERA

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

Who needs Chemo? Who does not? Is OFS plus endocrine...

ADAPT&ADAPTcylce

ESMO 2022

D. Lüftner, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

Status update - adjuvant IO. Are TILs prognostic?

KEYNOTE-522, Bellini

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

DATA: Still open questions on the optimal duration of...

DATA

ESMO 2022

V. Müller, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

Unmeet needs and my wishes for 2022!

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

Dose-dense CT Efficacy confirmed in the Nodal+ ER+...

GIM

ESMO 2022

V. Müller, V. Diéras, K. Gelmon, N. Harbeck, G. Curigliano, A. Gennari

Tailoring Adjuvant Therapy

ADAPT&ADAPTcycle, DATA, GIM

Breast cancer metastatic: 100 seconds ENG

ESMO 2022

Wolfgang Janni, MD

HER2+ and still without chemotherapy

monarcHER

ESMO 2022

Sara Tolaney, MD

CDK4/6i could be an option for selected ER+/HER2+...

monarcHER

ESMO 2022

Diana Lüftner, MD

ADC after ADC - is there any orientation?

TROPiCS-02

ESMO 2022

Carmen Criscitiello, MD

More therapy options for patients with HR+, HER2+...

monarcHER

ESMO 2022

Wolfgang Janni, MD

The third in the bunch

MONARCH-3

ESMO 2022

Diana Lüftner, MD

VEX has no place in chemotherapy of metastatic breast...

METEORA-II trial

ESMO 2022

Peter A. Fasching, MD

Interim analysis shows promising data on Abema in the...

MONARCH-3

ESMO 2022

Véronique Diéras, MD

New treatment option for heavily pre-treated patients...

TROPiCS-02

ESMO 2022

Volkmar Müller, MD

Survival benefit from SG in mBC

TROPiCS-02

ESMO 2022

Elzbieta Senkus-Konefka, MD

Endocrine-based therapy may prove more effective than...

MonarcHER

ESMO 2022

Barbara Pistilli, MD

Update on biomarkers on ADCs of the DAISY trial

DAISY

ESMO 2022

Véronique Diéras, MD

OS not significant, but re-assuring new data

MONARCH-3

ESMO 2022

Alessandra Gennari, MD

Survival benefit in endocrine sensitive patients

MONARCH3

ESMO 2022

Giuseppe Curigliano, MD

My highlights of ESMO22

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

Barbara Pistilli, MD

TROPiCS-02 highlights

TROPiCS-02

ESMO 2022

Sara Tolaney, MD

Discontinued development

Ameera

ESMO 2022

Hope Rugo, MD

New data re-inforces SG as a new option pre-treated...

TROPiCS-02

ESMO 2022

Alessandra Gennari, MD

Sacituzumab govitecan for everybody!

TROPiCS-02

ESMO 2022

Karen Gelmon, MD

Another option for heavily pre-treated HR+ advanced...

TROPiCS-02

ESMO 2022

Wolfgang Janni, MD

Negative and yet positive?!

AMEERA-3, acelERA BC

ESMO 2022

Carmen Criscitiello, MD

SG is a novel treatment option for HR+/HER2- disease

TROPiCS-02

ESMO 2022

Karen Gelmon, MD

Exciting data, but Phase 3 studies are needed

ELAINE

Breast cancer metastatic: 100 seconds Multi Language

ESMO 2022

Barbara Pistilli, MD

TROPiCS-02 highlights

TROPiCS-02

ESMO 2022

Carmen Criscitiello, MD

Nuove opzioni di trattamento personalizzate per...

monarcHER

ESMO 2022

Alessandra Gennari, MD

Sopravvivenza globale nello studio MONARCH3

MONARCH3

ESMO 2022

Véronique Diéras, MD

Survie globale pas encore significative statistiquement...

MONARCH-3

ESMO 2022

Elzbieta Senkus-Konefka, MD

Leczenie zaawansowanych raków „potrójnie dodatnich”...

MonarcHER

ESMO 2022

Alessandra Gennari, MD

Sacituzumab Govitecan: Un farmaco per tutte?

TROPiCS-02

ESMO 2022

Barbara Pistilli, MD

Nouvelles données des analyses expolratoires dans...

DAISY

ESMO 2022

Giuseppe Curigliano, MD

I miei punti salienti di ESMO22

TROPiCS-02, Monarch3, GIM, DATA

ESMO 2022

Véronique Diéras, MD

Nouvelle option thérapeutique pour les patientes...

TROPiCS-02

ESMO 2022

Carmen Criscitiello, MD

SG come nuova opzione di cura Per pazienti con tumore...

TROPiCS-02

Breast cancer metastatic: Discussions

ESMO 2022

W. Janni, S. Tolaney, H. Rugo, R. Dent, B. Pistilli, M. Untch

SERDs: equal PFS benefit vs. endocrine therapy;...

acelERA BC, AMEERA-3

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

ADC efficacy in perspective: SG overall survival...

TROPiCS

ESMO 2022

W. Janni, H. Rugo, R. Dent, S. Tolaney, B. Pistilli, M. Untch

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd...

TROPiCS-02

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

CDK4/6i plus Trastuzumab – a possible chemo-free option...

monacHER

ESMO 2022

M. Untch, R. Dent, H. Rugo, S. Tolaney, B. Pistilli, W. Janni

Monarch-3: strong OS Survival; DAWNA-2: PFS in line...

MONARCH 3, DAWNA-2, monarcHER

ESMO 2022

C. Criscitiello, N. Harbeck, E. Senkus-Konefka, P. A. Fasching

Interim OS Data & PFS Update for Abemaciclib hint...

MONARCH-3

NSCLC early stages: 100 seconds ENG

ESMO 2022

Stephen Liu, MD

ADAURA Update - preventing relapse or just delaying it?

ADAURA

ESMO 2022

Frank Griesinger, MD

Osimertinib stays standard adjuvant

ADAURA

ESMO 2022

Riyaz Shah, MD

Concurrent preoperative IO/CRT in early lung cancer

INCREASE

ESMO 2022

Lizza Hendriks, MD

Liquid biopsy monitoring of EGFR-mutant lung cancer...

ESMO 2022

Denis Moro-Sibilot, MD

Pollution and lung cancer - one mechanism revealed

ESMO 2022

Sacha Rothschild, MD

Long term follow-up of ADAURA trial

ADAURA

ESMO 2022

Riyaz Shah, MD

Is OS really needed?

ADAURA

ESMO 2022

Stephen Liu, MD

INCREASE - to good to be true?

INCREASE

ESMO 2022

Frank Griesinger, MD

Neoadjuvant strategies for PD-L1 < 1 %

INCREASE

ESMO 2022

Michael Thomas, MD

ADAURA revisited

ADAURA

ESMO 2022

Alfredo Addeo, MD

Osimertinib - curing or delaying relapse?

ADAURA

ESMO 2022

Michael Thomas, MD

Window for treatment selection

NeoCOAST

ESMO 2022

Lizza Hendriks, MD

Double IO + chemoradiotherapy - is it feasible in...

INCREASE

NSCLC early stages: 100 seconds Multi Language

ESMO 2022

Lizza Hendriks, MD

Dubbele immunotherapie plus chemoradiotherapie - is het...

INCREASE

ESMO 2022

Alfredo Addeo, MD

Osimertinib: una cura o ritarda la ripresa di malattia?

ADAURA

ESMO 2022

Sacha Rothschild, MD

Langzeitdaten ADAURA

ADAURA

ESMO 2022

Lizza Hendriks, MD

Liquid biopsie monitoring van patiënten met een EGFR...

ESMO 2022

Michael Thomas, MD

Eine Plattform für "take the winner"-Strategie

NeoCOAST

ESMO 2022

Frank Griesinger, MD

Osimertinib bleibt Standard adjuvant

ADAURA

ESMO 2022

Michael Thomas, MD

ADAURA revisited

ADAURA

ESMO 2022

Denis Moro-Sibilot, MD

Pollution et cancer du poumon - un mécanisme mis en...

NSCLC early stages - Discussion

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

Important data on borderline resectable patients

INCREASE, CheckMate 816

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

DFS matters!

ADAURA

NSCLC metastatic: 100 seconds ENG

ESMO 2022

Martin Reck, MD

Sotorasib vs. Docetaxel in mKRAS G12C

CodeBreak 200

ESMO 2022

Stephen Liu, MD

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

KEYNOTE-189, KEYNOTE-407

ESMO 2022

Martin Reck, MD

Can IO be discontinued?

DICIPLE

ESMO 2022

Frank Griesinger, MD

Cemiplimab beyond progression?

EMPOWER-Lung 1

ESMO 2022

Nicolas Girard, MD

Preview on lung cancer highlights

ESMO 2022

Michael Thomas, MD

5 years of chemoimmunotherapy: solid grounded

KEYNOTE-189, KEYNOTE-407

ESMO 2022

Hossein Borghaei, MD

Question about timing and duration of immunotherapy...

DICIPLE

ESMO 2022

Noemi Reguart, MD

New immunotherapy options for pts. ineligible to 1st...

IPSOS

ESMO 2022

Michael Thomas, MD

The journey at KRAS G12C continues

CodeBreaK 200

ESMO 2022

Alfredo Addeo, MD

Immunotherapy in unfit population? Perhaps...

IPSOS

ESMO 2022

Hossein Borghaei, MD

Sotorasib - a new standard of care?

CodeBreaK 200

ESMO 2022

Noemi Reguart, MD

Sotorasib: sweet and sour results

CodeBreaK 200

ESMO 2022

Denis Moro-Sibilot, MD

Chemoimmunotherapy - improvement of survival after 5...

KEYNOTE-189, KEYNOTE-407, POSEIDON

ESMO 2022

Lizza Hendriks, MD

Can we finally treat poor prognostic patients with...

IPSOS

ESMO 2022

Riyaz Shah, MD

5-year update on 1st line chemoimmunotherapy

KEYNOTE-189, KEYNOTE-407

ESMO 2022

Michael Thomas, MD

Emerging IO mono options in the first line

IPSOS

ESMO 2022

Alfredo Addeo, MD

One more brick in the KRAS G12C wall

CodeBreaK 200

ESMO 2022

Michael Thomas, MD

Poseidon and STK11/KEAP

POSEIDON

ESMO 2022

Martin Reck, MD

Atezolizumab better than vinorelbin in reduced...

IPSOS

ESMO 2022

Sacha Rothschild, MD

5-year data on survival under immunotherapy

KEYNOTE-189, KEYNOTE-407

ESMO 2022

Riyaz Shah, MD

HER2 - the next actionable mutation in lung cancer?

DESTINY-Lung02

ESMO 2022

Alfredo Addeo, MD

If you don't look, vou don't find - once you found it,...

ELIOS, INSIGHT 2

ESMO 2022

Denis Moro-Sibilot, MD

A new step in treatment of KRAS G12C mutant NSCLC

CodeBreaK 200

ESMO 2022

Denis Moro-Sibilot, MD

Duration of immunotherapy : Stop and go strategy for...

DICIPLE

ESMO 2022

Sacha Rothschild, MD

New therapy combination after progression on 1L...

INSIGHT 2

ESMO 2022

Frank Griesinger, MD

Liquid biopsy monitoring in treatment decisions

APPLE

ESMO 2022

Michael Thomas, MD

Pneumonitis and T-DXd

DESTINY-Lung02

ESMO 2022

Stephen Liu, MD

DESTINY-Lung02 - better than the original?

DESTINY-Lung02

ESMO 2022

Sacha Rothschild, MD

Is shorter immunotherapy equally effective and less...

DICIPLE

ESMO 2022

Nicolas Girard, MD

Real-world data on Atezolizumab

IMreal

ESMO 2022

Michael Thomas, MD

Induction chemoimmunotherapy in borderline...

INCREASE

NSCLC metastatic: 100 seconds Multi Language

ESMO 2022

Nicolas Girard, MD

Les études incontournables à l’ESMO 2022

ESMO 2022

Alfredo Addeo, MD

Se non lo cerchi non lo troiv. Quando lo hai trovato,...

ELIOS, INSIGHT 2

ESMO 2022

Sacha Rothschild, MD

5-Jahresüberleben mit Immuntherapie

Sacha Rothschild, MD

ESMO 2022

Nicolas Girard, MD

Données de vie réelle avec l’atezolizumab

IMreal

ESMO 2022

Michael Thomas, MD

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

INCREASE

ESMO 2022

Frank Griesinger, MD

IO-IO neoadjuvant bei PD-L1 neg.

INCREASE

ESMO 2022

Michael Thomas, MD

Poseidon und STK11/KEAP

POSEIDON

EMPOWER-Lung 1

Frank Griesinger, MD

Cemiplimab beyond progression?

ESMO 2022

Martin Reck, MD

Sotorasib vs. Docetaxel bei mKRAS G12C

CodeBreak 200

ESMO 2022

Michael Thomas, MD

Pneumonitis und T-DXd

DESTINY-Lung02

ESMO 2022

Martin Reck, MD

Kann IO pausiert werden?

DICIPLE

ESMO 2022

Martin Reck, MD

Atezo besser als Vino bei PS2-3

IPSOS

ESMO 2022

Michael Thomas, MD

Neue Option der IO-Therapie in der Erstlinie

IPSOS

ESMO 2022

Frank Griesinger, MD

Liquid Biopsy Monitoring zur Therapiesteuerung

APPLE

ESMO 2022

Michael Thomas, MD

Die Reise bei KRAS G12C geht weiter

CodeBreaK 200

ESMO 2022

Noemi Reguart, MD

Una nueva opción de tratamiento con IO en pacientes no...

IPSOS

ESMO 2022

Michael Thomas, MD

5 Jahre Chemo-Immuntherapie: starker Effekt

Keynote-189, KEYNOTE-407

ESMO 2022

Denis Moro-Sibilot, MD

Une nouvelle étape dans le traitement du CBNPC KRAS...

CodeBreaK 200

ESMO 2022

Alfredo Addeo, MD

Immunoterapia nella popolazione non fit: forse

IPSOS

ESMO 2022

Sacha Rothschild, MD

Neue Therapiekombination in der Resistenz nach...

INSIGHT 2

ESMO 2022

Denis Moro-Sibilot, MD

Durée de l'immunothérapie : stratégie Stop and Go pour...

DICIPLE

ESMO 2022

Noemi Reguart, MD

Resultados Agridulces de Sotorasib

CodeBreaK 200

ESMO 2022

Lizza Hendriks, MD

Kunnen we eindelijk patiënten met een slechte prognose...

IPSOS

ESMO 2022

Denis Moro-Sibilot, MD

Chimio-immunothérapie - amélioration de la survie après...

KEYNOTE-189, KEYNOTE-407, POSEIDON

ESMO 2022

Alfredo Addeo, MD

Un mattone in piu' nel muro del KRAS G12C

CodeBreaK 200

ESMO 2022

Sacha Rothschild, MD

Kürzere Immuntherapie gleich effektiv aber weniger...

DICIPLE

NSCLC metastatic - Discussions

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

A positive study! With a question mark?

CodeBreaK 200

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

Heterogenity in the genetic landscape - little progress...

APPLE, ELIOS, INSIGHT 2

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

New strategies in immunotherapy

DICIPLE, IPSOS

ESMO 2022

M. Reck, F. Griesinger, M. Thomas, R. Shah, N. Reguart, S. Liu, L. Hendricks,S. Rothschild, N. Girard

Novel data and long-term efficacy of chemo-IO in mNSCLC

EMPOWER-Lung 1, KEYNOTE-189, KEYNOTE-407

Kidney cancer: 100 seconds ENG

ESMO 2022

Philipp Ivanyi, MD

Adjuvant CPI in kidney cancer – 2 phase III trials with...

IMmotion010, CheckMate 914

ESMO 2022

Axel S. Merseburger, MD

Place of triplet therapy

COSMIC-313

ESMO22

Tom Powles, MD

Two negative studies question adjuvant approach in RCC

CheckMate914; IMmotion101

ESMO 2022

Joaquim Bellmunt, MD

Adjuvant Immuntherapy in kidney cancer

CheckMate914, IMmotion101, PROSPER

ESMO 2022

Thomas Powles, MD

More questions being raised

PROSPER

ESMO 2022

Ignacio Duran, MD

Immune-based peri-operative treatment in RCC: What went...

IMmotion101, Checkmate 914, PROSPER

ESMO 2022

Philipp Ivanyi, MD

News in terms of adjuvant

IMmotion010, CheckMate 914

ESMO 2022

Axel S. Merseburger, MD

No value of IPI/Nivo in the adjuvant setting.

CheckMate914

ESMO 2022

Petros Grivas, MD

Brief highlights about RCC & urothelial cancer from...

CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more

ESMO 2022

Joaquim Bellmunt, MD

New combo - triplet therapy for kidney cancer

COSMIC-313

ESMO 2022

P. Goebell, P. Ivanyi

Exciting data for high-risk patients: is this the start...

COSMIC-313

Kidney cancer: 100 seconds Multi Language

ESMO 2022

Petros Grivas, MD

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

CheckMate914, IMmotion101, PROSPER, COSMIC-313

ESMO 2022

Joaquim Bellmunt, MD

Inmunoterapia adyuvante en el cancer renales

CheckMate914, IMmotion101, PROSPER

ESMO 2022

Ignacio Duran, MD

Tratamiento perioperatorio con immunoterapia en cáncer...

IMmotion101, Checkmate 914, PROSPER

ESMO 2022

Joaquim Bellmunt, MD

Terapia triple para cancer renales

COSMIC-313

Kidney cancer: Discussions

ESO 2022

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

Adjuvant immunotherapy options in RCC - what do we...

CheckMate914, IMmotion101, PROSPER

ESMO 2022

P. J. Goebell, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

Immunomodulation in combination with...

PIVOT-09

ESMO 2022

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

Therapy combinations in RCC - what is the role of...

COSMIC-313, TITAN-RCC

ESMO 2022

P. J. Goebell, M.-O. Grimm, H. Hammers,T. Powles, S. K. Pal, P. Ivanyi

Shedding light on TKI/Checkpointinhibitor combinations

CLEAR, KEYNOTE-B61

Bladder cancer: 100 seconds ENG

ESMO 2022

Thomas Powles, MD

EV + Pembro with excellent response rates

EV-103 Cohort K

ESMO 2022

Petros Grivas, MD

Brief highlights about RCC & urothelial cancer from...

CheckMate914, IMmotion101, PROSPER, COSMIC-313, and more

ESMO 2022

Axel S. Merseburger, MD

EV + pembrolizumab in cisplatin-ineligible patients

LBA73

Bladder cancer: 100 seconds Multi Language

ESMO 2022

Petros Grivas, MD

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

EV-103, JAVELIN-Bladder100, IMvigor130

Bladder cancer: Discussions

ESMO 2022

L. Krabbe, P. Grivas, T. Powles, J. Bellmunt

Adjuvant and neoadjuvant therapy approaches in...

RACE IT

ESMO 2022

L. Krabbe, P. Grivas, T. Powles, J. Bellmunt, M.-O. Grimm

Promising data, but beware of toxicity

EV-103

ESMO 2022

M.-O. Grimm, P. Grivas, T. Powles, J. Bellmunt

Biomarker exploration in urothelial cancer - finding...

JAVELIN-Bladder100, IMvigor130

Prostate cancer: 100 seconds ENG

ESMO 2022

Gil Morgan, MD

In older vulnerable - less is more

CABASTY

ESMO 2022

Anders Bjartell, MD

Update on the PROpel study

PROpel

ESMO 2022

Axel S. Merseburger, MD

ADCs - a possible therapeutic approach

ESMO 2022

Marc-Oliver Grimm, MD; Laura-Maria Krabbe, MD

Optimizing cabazitaxel chemotherapy

CABASTY

ESMO 2022

Neal Shore, MD

Biomarker data for better patients selection

ENACT

ESMO 2022

Axel S. Merseburger, MD

Genetic testing before PARP therapy is useful

PROpel

ESMO 2022

Neal Shore, MD

IM arbiraterone decanoate might demonstrate superior...

P1/2a study of PRL-02

ESMO 2022

Axel S. Merseburger, MD

Cabazitaxel better tolerated in elderly men

ESMO 2022

Axel S. Merseburger, MD

IO + PARP without benefit in the allcomer situation

KEYLYNK-010

ESMO 2022

Anders Bjartell, MD

QoL data from ARASENS triplet therapy study mHRPC

ARASENS

ESMO 2022

Gil Morgan, MD

Should intensification of ADT be considered in...

PRESTO

ESMO 2022

Gil Morgan, MD

Radicals - ADT & Radiotherapy

RADICALS HD

ESMO 2022

Anders Bjartell, MD

PSA at 8-months as a biomarker

PEACE-1

ESMO 2022

Mar-Oliver Grimm, MD; Laura-Maria Krabbe, MD

Triplet therapy with darolutamide in prostate cancer

ARASENS

ESMO 2022

Gil Morgan, MD

Combination of olaparib leads to promising results

PROpel

ESMO 2022

Neal Shore, MD

Further evaluation of PSA correlates

VISION

ESMO 2022

Axel S. Merseburger, MD

Length of hormone therapy after radiation

RADICALS-HD

ESMO 2022

Neal Shore, MD

ADT + ENZA better choice than monotherapy

ARCHES

Prostate cancer: 100 seconds Multi Language

ESMO 2022

Anders Bjartell, MD

PSA efter 8 månader i PEACE-1 studien som biomarkör

PEACE-1

ESMO 2022

Anders Bjartell, MD

Uppdatering i PROpel studien

PROpel

ESMO 2022

Anders Bjartell, MD

Livskvalitetsuppföljning i ARASENS studien

ARASENS

Prostate cancer: Discussions

ESMO 2022

E. Efstathiou, M-O. Grimm, L. Krabbe, Y. Loriot, G. Morgan

Practice changing data - only for older and more...

CABASTY

ESMO 2022

A. Bjartell, L. Krabbe, Y. Loriot, A. Merseburger, D. Murphy,

Which men benefit from adding ADT?

RADICAL

ESMO 2022

A. Bjartell, Y. Loriot, A. Merseburger, G. Morgan, D. Murphy, N. Shore

Modern Imaging is the new standard

PRESTO

ESMO 2022

A. Merseburger, E. Efstathiou, N. Shore, D. Murphy, Y. Loriot

Positive results, but testing not that simple

STAMPEDE, PROpel

ESMO 2022

M-O Grimm, A. Bjartell, Y. Loriot, E. Efstathiou, G. Morgan, D. Murphy

PSA response after triplet therapy: What is the impact...

PEACE-1, ARASENS

Varia: 100 seconds ENG

ESMO 2022

Riyaz Shah, MD

Intimate partner violence in cancer patients

ESMO 2022

Philipp Ivanyi, MD

Novel approach von Biontech towards Cancer – game...

BNT211-01

ESMO 2022

Philipp Ivanyi, MD

Addition of CPI to Radiochemotherapy in LA-HNSCC?

KEYNOTE-412

ESMO 2022

Philipp Ivanyi, MD

TILs - Fashion is the eternal return of the old

ESMO 2022

Philipp Ivanyi, MD

New group of substances for rare diseases

DeFi

ESMO2 022

Philipp Ivanyi, MD

IAP-inhibition – comming game changer in LA-HNSCC...